Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer [0.03%]
乳腺癌中激酶抑制剂耐药的脂质代谢重组机制研究
William W Feng,Manabu Kurokawa
William W Feng
Breast cancer is one of the leading causes of death in women in the United States. In general, patients with breast cancer undergo surgical resection of the tumor and/or receive drug treatment to kill or suppress the growth of cancer cells....
Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs [0.03%]
DNA拓扑异构酶-DNA复合物的核苷酸/核苷类似物捕获机制
William H Gmeiner
William H Gmeiner
Topoisomerases are well-validated targets for cancer chemotherapy and DNA topoisomerase 1 (Top1) is the sole target of the camptothecin (CPT) class of anticancer drugs. Over the last 20 years, multiple studies have shown Top1 activity is mo...
Kelly M Kreitzburg,Robert C A M van Waardenburg,Karina J Yoon
Kelly M Kreitzburg
Despite progress in understanding molecular aberrations that contribute to the development and progression of ovarian cancer, virtually all patients succumb to drug resistant disease at relapse. Emerging data implicate bioactive sphingolipi...
Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts [0.03%]
靶向酪氨酰-DNA磷双酯酶I以增强DNA加合物毒性的磷酸二酯连接反应Intermediate Targeting Tdp1 to Enhance Toxicity of Phosphodiester Linked DNA AdductsIntermediate 酪氨酰-DNA磷双酯酶IIntermediate DNA加合物Intermediate 磷酸二酯连接Intermediate 毒性Intermediate
Evan J Brettrager,Robert C A M van Waardenburg
Evan J Brettrager
Our genomic DNA is under constant assault from endogenous and exogenous sources, which needs to be resolved to maintain cellular homeostasis. The eukaryotic DNA repair enzyme Tyrosyl-DNA phosphodiesterase I (Tdp1) catalyzes the hydrolysis o...
Mireia Cruz De Los Santos,Mihnea P Dragomir,George A Calin
Mireia Cruz De Los Santos
One of the major challenges in oncology is drug resistance, which triggers relapse and shortens patients' survival. In order to promote drug desensitization, cancer cells require the establishment of an ideal tumor microenvironment that acc...
MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution [0.03%]
神经母细胞瘤肿瘤发生、治疗抵抗及疾病进展中的微小核糖核酸
Natarajan Aravindan,Karthikeyan Subramanian,Dinesh Babu Somasundaram et al.
Natarajan Aravindan et al.
Neuroblastoma (NB) deriving from neural crest cells is the most common extra-cranial solid cancer at infancy. NB originates within the peripheral sympathetic ganglia in adrenal medulla and along the midline of the body. Clinically, NB exhib...
Natarajan Aravindan,Drishti Jain,Dinesh Babu Somasundaram et al.
Natarajan Aravindan et al.
Neuroblastoma (NB) is the most common cancer of infancy and accounts for nearly one tenth of pediatric cancer deaths. This mortality rate has been attributed to the > 50% frequency of relapse despite intensive, multimodal clinical therapy i...
Ping Fan,V Craig Jordan
Ping Fan
The translational research strategy of targeting estrogen receptor α (ERα) positive breast cancer and then using long term anti-hormone adjuvant therapy (5-10 years) has reduced recurrences and mortality. However, resistance continues to ...
Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas [0.03%]
识别并靶向CD22ΔE12作为针对高危B细胞白血病和淋巴瘤药物抵抗的分子RNAi靶点
Fatih M Uckun,Sanjive Qazi
Fatih M Uckun
Aim: CD22ΔE12 as an oncogenic driver lesion in aggressive and drug-resistant B-precursor acute lymphoblastic leukemia (BPL) cells. The purpose of the present study was to identify the CD22ΔE12-specific signature transcr...
Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors [0.03%]
睾丸生殖细胞肿瘤顺铂敏感和耐药的机制
Ratnakar Singh,Zeeshan Fazal,Sarah J Freemantle et al.
Ratnakar Singh et al.
Testicular germ cell tumors (TGCTs) are a cancer pharmacology success story with a majority of patients cured even in the highly advanced and metastatic setting. Successful treatment of TGCTs is primarily due to the exquisite responsiveness...